rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Cypherpunk Technologies Inc.

CYPH · Nasdaq

Health CareBiotechnologyIn trendCrypto

CYPH stood above a rising 150-day average in 29 of the last 52 weekly readings, including each of the last 7 weeks. It is 94.9% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
7 in a row
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$6.9M
Officials’ trades on record
0
Institutions holding
45 (+10)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 29 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$4.9M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months7
Buyers · sellers0 · 6
WhoDidSharesTraded
Khing Djien OeiDirectorsold168,750at $3.9225 Sep 2026filed 25 Sep 2026
Patricia A. MartinDirectorsold50,000at $3.8623 Sep 2026filed 25 Sep 2026
Thomas John DietzDirectorsold20,000at $1.7226 Aug 2026filed 27 Aug 2026
Christopher MirabelliDirectorsold60,000at $0.710526 Mar 2026filed 30 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders45+10 on the quarter
New · exited14 · 4
Reported value$8.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20263,887,574$2.4M+2,069,160+113.8%
BlackRock, Inc.added · filed 7 Aug 20262,622,823$1.6M+280,649+12.0%
JANE STREET GROUP, LLCnew · filed 14 Aug 20261,701,926$1.0M+1,701,926
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,173,737$719K+602,669+105.5%
UBS Group AGadded · filed 13 Aug 20261,127,366$690K+956,298+559.0%
CITADEL ADVISORS LLCnew · filed 14 Aug 2026836,153$512K+836,153
XTX Topco Ltdadded · filed 14 Aug 2026638,329$391K+607,671+1982.1%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026571,345$350K+274,259+92.3%
STATE STREET CORPadded · filed 7 Aug 2026516,113$316K+376,000+268.4%
NORTHERN TRUST CORPadded · filed 13 Aug 2026222,031$136K+134,469+153.6%
30 Jun 2023 – 30 Jun 2026
304253Jun 23Mar 24Dec 24Sep 25Jun 26

Everyone who traded it

William Patrick McEvoy III Company insiderChief Investment Officer · last 12 Oct 20260 · 0
Winklevoss Capital Fund, LLC Company insider10% owner · last 12 Oct 20260 · 0
Khing Djien Oei Company insiderDirector · last 25 Sep 20260 · 1
Patricia A. Martin Company insiderDirector · last 23 Sep 20260 · 1
Thomas John Dietz Company insiderDirector · last 26 Aug 20260 · 1
Kevin Zhang Company insiderHead of Mining · last 21 Aug 20260 · 0
Tyler Howard Winklevoss Company insider10% owner · last 17 Aug 20260 · 0
Christian M. Richard Company insiderDirector · last 1 Jul 20260 · 0
Douglas E. Onsi Company insiderCEO, CFO, Pres., GC, Treas.&Sec. · last 1 Jul 20262 · 1
Nissim Mashiach Company insiderDirector · last 1 Jul 20260 · 0
William Li Company insiderDirector · last 1 Jul 20260 · 0
Christopher Mirabelli Company insiderDirector · last 26 Mar 20262 · 2

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-25.9%
Cash conversionFY 2025 · to 31 Dec 2025-910%
Share count trendFY 2025 · to 11 Mar 20267.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$14.0M

Analyst forecasts

No analyst forecasts yet.